Table 1.

Serologic and Clinical Characteristics of Borrelia miyamotoi Infection in Study Patients^*

Group, Patient No., and Serum Phase†	Assay method			Coinfection‡	No. of symptoms
	ELISA	Western blot
		IgM	IgG
Group 1
Patient 1	Positive at 1:320 dilution	Positive	Positive	None	None
Patient 2	Positive at 1:320 dilution	Positive	Negative	None	None
Patient 3	Positive at 1:320 dilution	Positive	Positive	None	None
Patient 4	Positive at ≥1:320 dilution§	Not done	Positive	None	None
Patient 5	Positive at ≥1:320 dilution§	Not done	Positive	None	None
Patient 6	Positive at 1:320 dilution	Positive	Positive	None	None
Group 2
Patient 7	Positive at ≥1:320 dilution§	Not done	Positive	None	5
Patient 8	Positive at 1:320 dilution	Negative	Positive	None	9
Patient 9	Positive at 1:320 dilution	Negative	Positive	None	8
Patient 10	Positive at ≥1:320 dilution§	Not done	Positive	None	6
Patient 11	Positive at ≥1:320 dilution§	Not done	Positive	None	3
Patient 12	Positive at 1:1280 dilution	Negative	Positive	Lyme disease	4
Patient 13	Positive at 1:320 dilution	Negative	Positive	Lyme disease	Uncertain
Patient 14	Positive at 1:320 dilution	Positive	Positive	Lyme disease	Uncertain
Patient 15
Acute	Negative at 1:160 dilution	Negative	Negative	Babesiosis	12
Convalescent	Positive at 1:1280 dilution	Positive	Positive
Group 3
Patient 16	Positive at 1:1280 dilution	Positive	Positive	None	5
Patient 17
Acute	negative at 1:80 dilution	Positive	negative	None	10
Convalescent	Positive at 1:320 dilution	Positive	Positive
Patient 18
Acute	negative at 1:80 dilution	Positive	Positive	Lyme disease	12
Convalescent	Positive at 1:320 dilution	Negative	Positive

^*ELISA denotes enzyme-linked immunosorbent assay.

^†See text for the definition of various groups

^‡The diagnosis of Lyme disease was based on a typical erythema migrans skin lesion in Patients 12, 13, 14, and 18. Patients 8 and 16 had an atypical erythema migrans skin lesion (<5 cm in diameter).

^‡Tests to determine the presence of antibody in serum dilutions greater than 1:320 were not performed.